153 related articles for article (PubMed ID: 3004516)
61. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Mauler R; Merkle W; Hilfenhaus J
Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911
[TBL] [Abstract][Full Text] [Related]
62. Allogeneic single-donor cryoseal produced from fresh-frozen quarantine apheresis plasma as alternative for multidonor or autologous fibrin sealants.
Hazelaar S; Dijkstra-Tiekstra MJ; de Korte D; de Wildt-Eggen J
Transfusion; 2012 Mar; 52(3):517-23. PubMed ID: 21880042
[TBL] [Abstract][Full Text] [Related]
63. [Use of fibrin glue in 8 cases of arterial occlusive disease with or without patches].
Mozzillo N; Quarto G; Ottaviano A; Formato A; Molino C
Minerva Chir; 1986 Apr; 41(7):571-3. PubMed ID: 3487748
[No Abstract] [Full Text] [Related]
64. [Clinical experience with fibrin glue in periodontal surgery].
Caruso F; Serpico R; Laino G
Arch Stomatol (Napoli); 1984; 25(4):339-47. PubMed ID: 6336260
[No Abstract] [Full Text] [Related]
65. Fibrin glue.
Brennan M
Blood Rev; 1991 Dec; 5(4):240-4. PubMed ID: 1782483
[TBL] [Abstract][Full Text] [Related]
66. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products.
Chandra S; Groener A; Feldman F
Thromb Res; 2002 Mar; 105(5):391-400. PubMed ID: 12062540
[TBL] [Abstract][Full Text] [Related]
67. Inactivation of viruses and safety of stable plasma products.
Morgenthaler JJ
Beitr Infusionsther; 1989; 24():33-9. PubMed ID: 2481546
[TBL] [Abstract][Full Text] [Related]
68. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
Hilfenhaus J; Gröner A; Nowak T; Weimer T
Transfusion; 1997 Sep; 37(9):935-40. PubMed ID: 9308641
[TBL] [Abstract][Full Text] [Related]
69. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
[TBL] [Abstract][Full Text] [Related]
70. A review of clinical studies evaluating the efficacy of HIV inactivation methods.
Lawrence DN
Prog Clin Biol Res; 1990; 324():151-60. PubMed ID: 2308967
[TBL] [Abstract][Full Text] [Related]
71. A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus.
Hilfenhaus J; Geiger H; Lemp J; Hung CL
J Biol Stand; 1987 Jul; 15(3):251-63. PubMed ID: 3649341
[TBL] [Abstract][Full Text] [Related]
72. Plasma derivatives and viral hepatitis.
Gerety RJ; Aronson DL
Transfusion; 1982; 22(5):347-51. PubMed ID: 6812245
[TBL] [Abstract][Full Text] [Related]
73. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
Klamroth R; Gröner A; Simon TL
Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of the risk of hepatitis from clotting factor concentrates.
Fricke WA
Prog Clin Biol Res; 1990; 324():161-6. PubMed ID: 2408051
[No Abstract] [Full Text] [Related]
75. Securing viral safety for plasma derivatives.
Morgenthaler JJ
Transfus Med Rev; 2001 Jul; 15(3):224-33. PubMed ID: 11471124
[TBL] [Abstract][Full Text] [Related]
76. Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure.
Nowak T; Gregersen JP; Klockmann U; Cummins LB; Hilfenhaus J
J Med Virol; 1992 Mar; 36(3):209-16. PubMed ID: 1314286
[TBL] [Abstract][Full Text] [Related]
77. [Industrial pasteurization of plasma and criteria of quality].
Burnouf-Radosevich M; Burnouf T; Huart JJ
Rev Fr Transfus Hemobiol; 1993 Jan; 36(1):93-102. PubMed ID: 8476493
[TBL] [Abstract][Full Text] [Related]
78. Inactivation of viruses in therapeutic products derived from human plasma.
Mitra G; Dobkin MB; Louie RE; Mozen MM
Am J Med; 1988 Jun; 84(6A):87-90. PubMed ID: 2837900
[TBL] [Abstract][Full Text] [Related]
79. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates.
Burnouf T
Biologicals; 1992 Jun; 20(2):91-100. PubMed ID: 1389114
[TBL] [Abstract][Full Text] [Related]
80. Inactivation of viruses related to hepatitis C virus by pasteurization in human plasma derivatives.
Nowak T; Klockman U; Hilfenhaus J
Biologicals; 1992 Mar; 20(1):83-5. PubMed ID: 1319182
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
